Kashiv BioSciences, LLC
http://www.kashivbiosciences.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kashiv BioSciences, LLC
Keeping Track: Pediatric Approvals, Seres Starts C Diff Submission, And BMS Pulls Reblozyl sBLA Before Possible CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
US Biosimilar Market – Who's In It For The Long Haul?
A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?
Facing Regulatory Heat, Indian Pharma Turns To Quality Solutions
Against a backdrop of US FDA warnings and global regulatory convergence, the Indian pharma industry is looking to build in quality from project inception and foster an unbiased approach to quality across global markets, a conference in Mumbai hears.
Pfizer Is King Of The US Biosimilar Hill
Four biosimilar candidates are under US FDA review, including what could be Pfizer’s eighth biologic approved under FDA’s 351(k) biologics license application pathway.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Other Names / Subsidiaries
-
- Adello Biologics, LLC
- Kashiv Pharma, LLC
- TheraProteins
- Therapeutic Proteins International
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice